The US FDA has approved Ycanth (cantharidin) topical solution for adult & pediatric patients aged ≥2yrs. with molluscum contagiosum. The approval was based on 2 P-III trials (CAMP-1 & 2) that evaluated VP-102 (Ycanth) vs PBO in patients aged ≥2yrs.
Both trial results showed that patients treated with VP-102 met its 1EPs of complete clearance of all treatable molluscum lesions, 46% vs 18% achieved complete clearance of molluscum lesions in the (CAMP-1) trial while 54% vs 13% in the (CAMP-2) trial
In an additional post-hoc analysis, complete clearance of all lesions was higher in the VP-102 group vs vehicle across all body regions. Ycanth, a drug-device combination product administered by a healthcare professional is expected to be available in Sept 2023
Ref: Globenewswire | Image: Merck
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
